Table of Contents

Executive Summary

1 Industry Overview of Anal Cancer

• 1.1 Definition of Anal Cancer
• 1.2 Anal Cancer Segment by Type
  • 1.2.1 Global Anal Cancer Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 Fluorouracil
  • 1.2.3 Cisplatin
  • 1.2.4 Carboplatin
  • 1.2.5 Other
• 1.3 Anal Cancer Segment by Applications
  • 1.3.1 Global Anal Cancer Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Hospitals
  • 1.3.3 Long-term care centers
  • 1.3.4 Pharmacies
  • 1.3.5 Other
• 1.4 Global Anal Cancer Overall Market
  • 1.4.1 Global Anal Cancer Revenue (2014-2025)
  • 1.4.2 Global Anal Cancer Production (2014-2025)
  • 1.4.3 North America Anal Cancer Status and Prospect (2014-2025)
  • 1.4.4 Europe Anal Cancer Status and Prospect (2014-2025)
  • 1.4.5 China Anal Cancer Status and Prospect (2014-2025)
  • 1.4.6 Japan Anal Cancer Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Anal Cancer Status and Prospect (2014-2025)
  • 1.4.8 India Anal Cancer Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Anal Cancer
• 2.3 Manufacturing Process Analysis of Anal Cancer
• 2.4 Industry Chain Structure of Anal Cancer

3 Development and Manufacturing Plants Analysis of Anal Cancer

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Anal Cancer Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Anal Cancer
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Anal Cancer Production and Capacity Analysis
• 4.2 Anal Cancer Revenue Analysis
• 4.3 Anal Cancer Price Analysis
• 4.4 Market Concentration Degree

5 Anal Cancer Regional Market Analysis

• 5.1 Anal Cancer Production by Regions
  • 5.1.1 Global Anal Cancer Production by Regions
  • 5.1.2 Global Anal Cancer Revenue by Regions
• 5.2 Anal Cancer Consumption by Regions
• 5.3 North America Anal Cancer Market Analysis
  • 5.3.1 North America Anal Cancer Production
  • 5.3.2 North America Anal Cancer Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Anal Cancer Import and Export
• 5.4 Europe Anal Cancer Market Analysis
  • 5.4.1 Europe Anal Cancer Production
  • 5.4.2 Europe Anal Cancer Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Anal Cancer Import and Export
• 5.5 China Anal Cancer Market Analysis
  • 5.5.1 China Anal Cancer Production
  • 5.5.2 China Anal Cancer Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Anal Cancer Import and Export
• 5.6 Japan Anal Cancer Market Analysis
  • 5.6.1 Japan Anal Cancer Production
  • 5.6.2 Japan Anal Cancer Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Anal Cancer Import and Export
• 5.7 Southeast Asia Anal Cancer Market Analysis
  • 5.7.1 Southeast Asia Anal Cancer Production
  • 5.7.2 Southeast Asia Anal Cancer Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Anal Cancer Import and Export
• 5.8 India Anal Cancer Market Analysis
  • 5.8.1 India Anal Cancer Production
  • 5.8.2 India Anal Cancer Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Anal Cancer Import and Export

6 Anal Cancer Segment Market Analysis (by Type)

• 6.1 Global Anal Cancer Production by Type
• 6.2 Global Anal Cancer Revenue by Type
• 6.3 Anal Cancer Price by Type

7 Anal Cancer Segment Market Analysis (by Application)

• 7.1 Global Anal Cancer Consumption by Application
• 7.2 Global Anal Cancer Consumption Market Share by Application (2014-2019)

8 Anal Cancer Major Manufacturers Analysis

• 8.1 GlaxoSmithKline
  • 8.1.1 GlaxoSmithKline Anal Cancer Production Sites and Area Served
  • 8.1.2 GlaxoSmithKline Product Introduction, Application and Specification
  • 8.1.3 GlaxoSmithKline Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 Spectrum Pharmaceuticals
  • 8.2.1 Spectrum Pharmaceuticals Anal Cancer Production Sites and Area Served
  • 8.2.2 Spectrum Pharmaceuticals Product Introduction, Application and Specification
  • 8.2.3 Spectrum Pharmaceuticals Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Hospira
  • 8.3.1 Hospira Anal Cancer Production Sites and Area Served
  • 8.3.2 Hospira Product Introduction, Application and Specification
  • 8.3.3 Hospira Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Global BioPharma
  • 8.4.1 Global BioPharma Anal Cancer Production Sites and Area Served
  • 8.4.2 Global BioPharma Product Introduction, Application and Specification
  • 8.4.3 Global BioPharma Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Advaxis
  • 8.5.1 Advaxis Anal Cancer Production Sites and Area Served
  • 8.5.2 Advaxis Product Introduction, Application and Specification
  • 8.5.3 Advaxis Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Amgen Inc
  • 8.6.1 Amgen Inc Anal Cancer Production Sites and Area Served
  • 8.6.2 Amgen Inc Product Introduction, Application and Specification
  • 8.6.3 Amgen Inc Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 Atara Biotherapeutics
  • 8.7.1 Atara Biotherapeutics Anal Cancer Production Sites and Area Served
  • 8.7.2 Atara Biotherapeutics Product Introduction, Application and Specification
  • 8.7.3 Atara Biotherapeutics Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 Bayer
  • 8.8.1 Bayer Anal Cancer Production Sites and Area Served
  • 8.8.2 Bayer Product Introduction, Application and Specification
  • 8.8.3 Bayer Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 Cell Medica
  • 8.9.1 Cell Medica Anal Cancer Production Sites and Area Served
  • 8.9.2 Cell Medica Product Introduction, Application and Specification
  • 8.9.3 Cell Medica Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Eli Lilly
  • 8.10.1 Eli Lilly Anal Cancer Production Sites and Area Served
  • 8.10.2 Eli Lilly Product Introduction, Application and Specification
  • 8.10.3 Eli Lilly Anal Cancer Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 Genticel
• 8.12 ISA Pharmaceuticals
• 8.13 Merck＆Co
• 8.14 Millennium Pharmaceuticals
• 8.15 Novartis
• 8.16 ​​Ono Pharmaceutical
• 8.17 Oryx
• 8.18 PDS Biotechnology
• 8.19 Sun Pharma

9 Development Trend of Analysis of Anal Cancer Market

• 9.1 Global Anal Cancer Market Trend Analysis
  • 9.1.1 Global Anal Cancer Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Anal Cancer Regional Market Trend
  • 9.2.1 North America Anal Cancer Forecast 2019-2025
  • 9.2.2 Europe Anal Cancer Forecast 2019-2025
  • 9.2.3 China Anal Cancer Forecast 2019-2025
  • 9.2.4 Japan Anal Cancer Forecast 2019-2025
  • 9.2.5 Southeast Asia Anal Cancer Forecast 2019-2025
  • 9.2.6 India Anal Cancer Forecast 2019-2025
• 9.3 Anal Cancer Market Trend (Product Type)
• 9.4 Anal Cancer Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Anal Cancer Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List

Anal cancer is a disease in which malignant (cancer) cells form in the tissues of the anus. Being infected with the human papillomavirus (HPV) increases the risk of developinganal cancer. Signs of anal cancer include bleeding from theanus or rectum or a lump near the anus.

The global Anal Cancer market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Anal Cancer volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anal Cancer market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Anal Cancer in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Anal Cancer manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GlaxoSmithKline
Spectrum Pharmaceuticals
Hospira
Global BioPharma
Advaxis
Amgen Inc
Atara Biotherapeutics
Bayer
Cell Medica
Eli Lilly
Genticel
ISA Pharmaceuticals
Merck＆Co
Millennium Pharmaceuticals
Novartis
​​Ono Pharmaceutical
Oryx
PDS Biotechnology
Sun Pharma

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Fluorouracil
Cisplatin
Carboplatin
Other

Segment by Application
Hospitals
Long-term care centers
Pharmacies
Other